500,000 Shares in Alector, Inc. $ALEC Bought by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC bought a new position in shares of Alector, Inc. (NASDAQ:ALEC) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 500,000 shares of the company’s stock, valued at approximately $1,075,000. Affinity Asset Advisors LLC owned about 0.45% of Alector at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ALEC. Spruce Street Capital LP lifted its stake in shares of Alector by 87.9% in the first quarter. Spruce Street Capital LP now owns 2,101,068 shares of the company’s stock worth $4,517,000 after buying an additional 983,082 shares during the last quarter. Sei Investments Co. boosted its stake in Alector by 218.9% during the 1st quarter. Sei Investments Co. now owns 53,846 shares of the company’s stock valued at $116,000 after purchasing an additional 36,962 shares during the period. Dimensional Fund Advisors LP boosted its stake in Alector by 42.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 283,817 shares of the company’s stock valued at $610,000 after purchasing an additional 84,691 shares during the period. Bank of New York Mellon Corp grew its holdings in Alector by 15.8% in the 1st quarter. Bank of New York Mellon Corp now owns 252,297 shares of the company’s stock valued at $542,000 after buying an additional 34,435 shares during the last quarter. Finally, Diversified Trust Co grew its holdings in Alector by 83.6% in the 1st quarter. Diversified Trust Co now owns 25,895 shares of the company’s stock valued at $56,000 after buying an additional 11,793 shares during the last quarter. 85.83% of the stock is currently owned by institutional investors.

Alector Trading Down 0.7%

NASDAQ ALEC opened at $1.48 on Friday. The company has a market cap of $164.32 million, a PE ratio of -1.24 and a beta of 0.60. The company has a current ratio of 5.25, a quick ratio of 5.25 and a debt-to-equity ratio of 0.80. The stock has a 50 day moving average of $1.80 and a 200-day moving average of $2.02. Alector, Inc. has a 12 month low of $1.09 and a 12 month high of $3.40.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. The business had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $9.67 million. Alector had a negative return on equity of 295.17% and a negative net margin of 680.83%. On average, equities research analysts anticipate that Alector, Inc. will post -0.86 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Neil Lindsay Berkley sold 19,360 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total value of $38,139.20. Following the transaction, the chief financial officer directly owned 379,900 shares in the company, valued at approximately $748,403. This represents a 4.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Arnon Rosenthal sold 87,216 shares of Alector stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total transaction of $171,815.52. Following the completion of the sale, the chief executive officer owned 2,367,206 shares of the company’s stock, valued at $4,663,395.82. This trade represents a 3.55% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 115,760 shares of company stock valued at $227,734 in the last three months. Insiders own 8.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ALEC. Cantor Fitzgerald raised Alector from a “neutral” rating to an “overweight” rating in a research report on Wednesday, April 15th. Wall Street Zen raised shares of Alector from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Morgan Stanley reissued an “underweight” rating and issued a $2.00 price target on shares of Alector in a report on Monday, May 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Alector in a research report on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $3.62.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.